ANAPTYSBIO, INC(ANAB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,725 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ANAB Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ANAPTYSBIO, INC (ANAB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANAB at 48.4/100 on a 32-signal composite quality model, placing it at rank #1,725 of 2,962 stocks — the bottom half of the AI-ranked universe. ANAB scores in the top quartile across revenue growth (99.3), institutional flow (85.7). Areas of concern include balance sheet strength (19.8) and profitability (25.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ANAPTYSBIO, INC reports quarterly revenue of $25.6M, net income of $-52.9M, free cash flow of $-25.9M. Top institutional holders of ANAB by reported 13-F value include EcoR1 Capital, BlackRock, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. ANAB trades on the Nasdaq exchange and files with the SEC under CIK 1370053. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANAPTYSBIO, INC directly from SEC EDGAR. ANAPTYSBIO, INC's 13F Pro composite quality score has ranged between 9 and 50 since 2021, currently 48.4 — an improving long-term trajectory across 67 quarterly and live scoring snapshots.
Revenue
Q1 2026
$25.6M
Net Income
Q1 2026
$-52.9M
Free Cash Flow
Q1 2026
$-25.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+157.0% YoYNet Income
+90.9% YoYOperating Income
+141.7% YoYEPS (Diluted)
+91.0% YoYTotal Assets
-24.7% YoYOp. Cash Flow
+114.6% YoYFree Cash Flow
+114.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $234.6M +157.0% | $91.3M +432.0% | $17.2M +66.8% | $10.3M -83.7% | $63.2M -15.8% | $75.0M |
| Net Income | $-13.2M +90.9% | $-145.2M +11.2% | $-163.6M -27.1% | $-128.7M -122.7% | $-57.8M -190.0% | $-19.9M |
| Operating Income | $47.9M +141.7% | $-114.9M +30.1% | $-164.4M -42.8% | $-115.2M -102.7% | $-56.8M -137.9% | $-23.9M |
| EPS (Diluted) | $-0.46 +91.0% | $-5.12 +15.8% | $-6.08 -33.0% | $-4.57 -116.6% | $-2.11 -189.0% | $-0.73 |
| Total Assets | $364.4M -24.7% | $483.8M +7.0% | $452.4M -25.9% | $610.4M -5.1% | $643.1M +54.4% | $416.6M |
| Operating Cash Flow | $19.7M +114.6% | $-135.3M -12.0% | $-120.8M -64.1% | $-73.6M -60.3% | $-45.9M -224.4% | $-14.2M |
| Free Cash Flow | $19.6M +114.5% | $-135.7M -11.6% | $-121.6M -64.4% | $-74.0M -56.4% | $-47.3M -221.1% | $-14.7M |
Get alerted when ANAB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ANAPTYSBIO, INC including:
Top Institutional Holders of ANAB
EcoR1 Capital, LLC
$531.9M7,880,094 shBlackRock, Inc.
$124.5M1,844,049 shTANG CAPITAL MANAGEMENT LLC
$89.8M1,330,879 shSTATE STREET CORP
$86.8M1,286,194 shVANGUARD CAPITAL MANAGEMENT LLC
$61.2M906,233 shAffinity Asset Advisors, LLC
$55.8M826,109 shSanofi
$55.5M821,917 shMILLENNIUM MANAGEMENT LLC
$54.5M807,316 shWoodline Partners LP
$48.4M717,014 sh683 Capital Management, LLC
$44.6M660,000 sh
| Fund | Value | Shares |
|---|---|---|
| EcoR1 Capital, LLC | $531.9M | 7,880,094 |
| BlackRock, Inc. | $124.5M | 1,844,049 |
| TANG CAPITAL MANAGEMENT LLC | $89.8M | 1,330,879 |
| STATE STREET CORP | $86.8M | 1,286,194 |
| VANGUARD CAPITAL MANAGEMENT LLC | $61.2M | 906,233 |
| Affinity Asset Advisors, LLC | $55.8M | 826,109 |
| Sanofi | $55.5M | 821,917 |
| MILLENNIUM MANAGEMENT LLC | $54.5M | 807,316 |
| Woodline Partners LP | $48.4M | 717,014 |
| 683 Capital Management, LLC | $44.6M | 660,000 |
Companies Similar to ANAB
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Inhibrx Biosciences, Inc.
Verastem, Inc.
ARDELYX, INC.
Phathom Pharmaceuticals, Inc.
SI-BONE, Inc.
Axogen, Inc.
Ultragenyx Pharmaceutical Inc.
RHYTHM PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ANAB on your watchlist
Track score changes the day ANAPTYSBIO, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ANAB a good stock to buy?
13F Pro's AI-powered analysis of ANAPTYSBIO, INC (ANAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANAB are available on the ANAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ANAB is classified as a small company.
Which hedge funds own ANAB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ANAPTYSBIO, INC's investment landscape.